Bayer's Balance Sheet Gets a $3 Billion Assist While Kerendia Breaks a 30-Year Drought

FDA clears Kerendia for chronic kidney disease in type 1 diabetics, a first in about 30 years, as Bayer's Apollo deal cuts net debt guidance.

Bayer has spent years fighting on two fronts that rarely move in tandem: a courtroom and a laboratory. This week, the laboratory side delivered a headline that the company's balance sheet had already been quietly preparing investors for.

The US Food and Drug Administration on Thursday cleared Kerendia (finerenone) for a new indication — chronic kidney disease in adults with type 1 diabetes. It marks the first new treatment option for that patient population in the United States in roughly three decades, and the third approved use for the active ingredient. Between 20% and 30% of American type 1 diabetics develop the kidney condition, according to company figures.

The decision rests on the Phase III FINE-ONE trial, which enrolled 242 participants and was published in the NEJM in March. Over three months, the study recorded a 22% reduction in the urine albumin-to-creatinine ratio (UACR) versus placebo, widening to 28% at six months. The result carried a p-value of 0.0001. Hyperkalemia appeared in 10.1% of treated patients against 3.3% on placebo. The FDA handled the application under priority review, a signal of the unmet need the agency saw in the indication.

Kerendia was already approved for chronic kidney disease in type 2 diabetics and for heart failure. The latest label expansion is the first worldwide authorization for this specific group — the US is the first country to grant it.

A financing structure that reshapes the debt picture

The regulatory win lands alongside a balance-sheet overhaul that has been in motion since July. Bayer's partnership with Apollo, announced that month, funnels EUR 3.0 billion into a newly created subsidiary housing the company's long-acting reversible contraceptive (LARC) business. Apollo takes a non-controlling minority stake; Bayer keeps both the majority holding and operational control.

The capital injection moved the needle on a metric that has dogged the Leverkusen-based group for years. Net financial debt for the current fiscal year is now guided to a range of EUR 29 billion to EUR 30 billion, down from an original projection of EUR 32 billion to EUR 33 billion.

That improvement sits on top of a reaffirmed outlook. When Bayer reported half-year figures in early August, it stood by its 2026 guidance: adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion, and core earnings per share of EUR 4.30 to EUR 4.90.

Second-quarter 2026 revenue rose 2.2% year on year on a currency- and portfolio-adjusted basis to EUR 10.87 billion. Adjusted EBITDA advanced 1.9% to EUR 2.14 billion.

Pharma pipeline adds depth beyond a single drug

Kerendia is not carrying the pharma story alone. First-half 2026 sales of the kidney drug jumped 75%, surpassing EUR 600 million well before the new US label came through. Bayer projects peak annual sales above EUR 3 billion for the product across all indications.

Elsewhere in the portfolio, the lung cancer drug Hyrnuo secured FDA clearance after winning Japanese approval. In May, Bayer bolstered its ophthalmology pipeline by acquiring Perfuse Therapeutics, a deal worth up to USD 2.45 billion — a USD 300 million upfront payment plus potential milestone payments.

What the analysts and the tape are saying

The improved capital structure drew a swift response from the sell side. Barclays raised its price target on Bayer to EUR 70 from EUR 60 on September 7, keeping an "Overweight" rating. UBS had already reaffirmed its buy recommendation with a EUR 62 target on September 1.

In Frankfurt, the shares closed Thursday at EUR 49.17, up 0.7% on the day. Intraday trading around the Kerendia news had the stock at EUR 49.15, a 0.6% gain, with a 1.4% advance over the past week — enough to frame the move as an extension of the recent trend rather than a one-off spike.

Year to date, the equity is up 33%; over twelve months, 78%. The 52-week high of EUR 53.86, set in early July, remains 8.7% away. Bayer's market capitalization stands at EUR 48.46 billion.

The glyphosate litigation has not disappeared, and Crop Science plus the Roundup legacy remain fixtures on investors' radar. But the Apollo transaction has given Bayer something it long lacked: a way to unlock capital from a strategic business without surrendering control of it. Whether Kerendia's momentum shows up in the next set of quarterly numbers is now the question traders are positioning around.